RxDoctor Payments Data

Joline Brotzman

Psychiatric/Mental Health · Fond du Lac, WINPI 1578813606

Payments from drug & device makers

$1,882in general payments, 2019–2025

Across 111 payments — averaging $16.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$412
  • Alkermes, Inc.$397
  • Otsuka America Pharmaceutical, Inc.$202
  • Lundbeck LLC$187
  • Takeda Pharmaceuticals U.S.A., Inc.$135
  • Indivior Inc.$100
  • plus $448 from 9 others

What the payments were for

  • Food & beverage$1,882100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,882 in reported general payments places this provider in the 75th percentile of 384 psychiatric/mental health providers in Wisconsin.

See all psychiatric/mental health providers in Wisconsin

Medicare billing

Part B allowed, 2024
$18,201
Medicare patients
59
Services billed
264

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate30$256,392
VraylarCariprazine Hcl96$138,632
Abilify MaintenaAripiprazole41$120,180
Invega SustennaPaliperidone Palmitate26$80,206
Risperdal ConstaRisperidone Microspheres20$58,502
RexultiBrexpiprazole44$53,615
Fluphenazine Hcl145$27,257
CaplytaLumateperone Tosylate16$24,849
Aripiprazole143$18,852
BelsomraSuvorexant34$15,508
Clozapine184$10,713
Lurasidone Hcl57$10,115
Fluphenazine Decanoate95$10,103
Haloperidol118$6,283
Divalproex Sodium ErDivalproex Sodium164$6,029

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$28$256,39230 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$202$173,79585 claims
Johnson & JohnsonInvega Sustenna, Risperdal Consta$81$138,70746 claims
AbbVieVraylar$412$138,63296 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$68$24,84916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 384 psychiatric/mental health providers in Wisconsin.

Other psychiatric/mental health in Fond du Lac

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →